Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 4

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Vanderbilt University Medical Center · with ACADIA Pharmaceuticals Inc. · NCT05357612

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 50–85 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 4
Target enrollment
75
US sites recruiting
1
Study start
January 23, 2023
Record last updated
August 7, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-[18F]MH.MZ in both populations.

Being studied: Pimavanserin

Conditions: Neurodegenerative Diseases; Parkinson Disease; Parkinson Disease Psychosis

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Patient arm - clinical diagnosis of Parkinson disease, diffuse Lewy body disease, multiple systems atrophy, Huntington's Disease, Frontotemporal Dementia, and other variants
  • Healthy arm - age and gender matched to patient arm
  • Psychosis (presence of hallucinations or delusions) starting after the diagnosis of Parkinson's disease, occurring at least weekly for 4 weeks, severe enough to warrant treatment.
  • Study partner available for study visits

Exclusion Criteria

  • Prior stroke or other uncontrolled serious neurological or medical illness
  • Contra-indication or inability to tolerate MRI scan
  • Use of serotonergic medications in the last 6 weeks
  • Incapable of providing independent consent.
  • Pregnant or breastfeeding women
  • psychosis due to a metabolic, toxic, or primary psychiatric disease
  • Deemed unable to complete neurocognitive testing
  • For PD Participants: current or prior use of pimavanserin
  • Use of antipsychotics in the last 2 weeks

Recruiting US locations

  • Vanderbilt University Medical Center

    Nashville, TN 37212

    Site contact: Levi Pettit, BA · 615-421-0569 · levi.f.pettit@vumc.org

Study contacts (from the official record)

  • Levi Pettit, BA · 6154210569 · levi.f.pettit@vumc.org
  • Katie Hay, MS · kaitlyn.r.hay@vumc.org
All mental health studies in Tennessee →
Characterization of the Serotonin 2A Receptor Selective PET Tracer… (NCT05357612) | Bored Studies